Verona's ensifentrine misses in Phase II for COPD maintenance
Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease (COPD).
Both twice-daily 1.5 and 6 mg doses of ensifentrine plus inhaled Spiolto Respimat tiotropium/olodaterol failed to significantly improve peak forced expiratory volume in 1 second (FEV1) at four hours post-dose after the morning dose on day three vs. placebo plus Spiolto Respimat. Both doses of ensifentrine plus Spiolto Respimat did significantly improve peak FEV1 after the evening dose on day three vs. placebo plus Spiolto Respimat (improvements of 130 and 81 mL, respectively, p<0.001 and p=0.002)...